ArticleNeuropharmacology2020
c-Jun N terminal kinase signaling pathways mediate cannabinoid tolerance in an agonist-specific manner.
Open access · greenAbstract read
In one paragraph
Article in Neuropharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Canonical Cannabinoid Receptors.Current topics in behavioral neurosciences · 2026Review
- Fused in Sarcoma (FUS) promotes renal cell carcinoma progression via the KCMF1/FUS/CENPT axis and activation of the JNK signaling pathway.Journal of translational medicine · 2025Article
- Cannabinoid overrides triggers of GABAergic plasticity in vestibular circuits and distorts the development of navigation.iScience · 2025Article
- Article
- Chronic Administration of Cannabinoid Agonists ACEA, AM1241, and CP55,940 Induce Sex-Specific Differences in Tolerance and Sex Hormone Changes in a Chemotherapy-Induced Peripheral Neuropathy.The Journal of pharmacology and experimental therapeutics · 2024Article
- Review
- Antinociceptive Effects of Cannabichromene (CBC) in Mice: Insights from von Frey, Tail-Flick, Formalin, and Acetone Tests.Biomedicines · 2023Article
- Sex differences in acute delta-9-tetrahydrocannabinol (ΔPsychopharmacology · 2023Article
- Mechanisms of cannabinoid tolerance.Biochemical pharmacology · 2023Review
- Cannabinoid Tolerance in S426A/S430A xThe Journal of pharmacology and experimental therapeutics · 2023Article
- Evaluating the Antinociceptive Efficacy of Cannabidiol Alone or in Combination with Morphine Using the Formalin Test in Male and Female Mice.Cannabis and cannabinoid research · 2022Article
- Sex-specific mechanisms of tolerance for the cannabinoid agonists CP55,940 and delta-9-tetrahydrocannabinol (ΔPsychopharmacology · 2022Article
- Decursinol-mediated antinociception and anti-allodynia in acute and neuropathic pain models in male mice: Tolerance and receptor profiling.Frontiers in pharmacology · 2022Article
- Sex and dose-dependent antinociceptive effects of the JNK (c-Jun N-terminal kinase) inhibitor SU 3327 are mediated by CBBrain research bulletin · 2021Article
- Cannabis use, abuse, and withdrawal: Cannabinergic mechanisms, clinical, and preclinical findings.Journal of neurochemistry · 2021Review
- Cannabinoid Modulation of Dopamine Release During Motivation, Periodic Reinforcement, Exploratory Behavior, Habit Formation, and Attention.Frontiers in synaptic neuroscience · 2021Review
- Chronic cannabinoid exposure produces tolerance to the dopamine releasing effects of WIN 55,212-2 and heroin in adult male rats.Neuropharmacology · 2021Article
- Sex Differences in Tolerance to Delta-9-Tetrahydrocannabinol in Mice With Cisplatin-Evoked Chronic Neuropathic Pain.Frontiers in molecular biosciences · 2021Article
- A cellular perspective of bias at G protein-coupled receptors.Protein science : a publication of the Protein Society · 2020Review
- Protein Interactors and Trafficking Pathways That Regulate the Cannabinoid Type 1 Receptor (CB1R).Frontiers in molecular neuroscience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Angela N Henderson-RedmondDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA.
Caitlin M NealonDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA.
Brian J DavisGill Center for Biomolecular Science, Indiana University, Bloomington, IN, 47405, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, 47405, USA.
Matthew B YuillDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA.
Diana E SepulvedaDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA.
Henry L BlantonDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA.
Mary K PiscuraDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA.
Michael L ZeeDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, 47405, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, 47405, USA.
Chris P HaskinsDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, 47405, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, 47405, USA.
David J MarcusDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA; Gill Center for Biomolecular Science, Indiana University, Bloomington, IN, 47405, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, 47405, USA.
Ken MackieGill Center for Biomolecular Science, Indiana University, Bloomington, IN, 47405, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, 47405, USA.
Josée GuindonDepartment of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, Lubbock, TX, 79430, USA. Electronic address: josee.guindon@ttuhsc.edu.
Daniel J MorganDepartment of Anesthesiology and Perioperative Medicine, Penn State University College of Medicine, Hershey, PA, 17033, USA. Electronic address: djm68@psu.edu.
Pennsylvania State University · USIndiana University Bloomington · USTexas Tech University Health Sciences Center · US
Funding
Project 3 - In vivo pharmacology of cannabinoid receptor probesP01DA009158 · NIDA · UNIVERSITY OF CONNECTICUT STORRS · PI Alexandros Makriyannis · 1994 to 2026
$26.0MNeuronal cannabinoidsR01DA011322 · NIDA · UNIVERSITY OF WASHINGTON · PI MACKIE, KENNETH · 1998 to 2014
$3.4MMechanisms of cannabinoid toleranceR01DA044999 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI GUINDON, JOSEE, MORGAN, DANIEL J · 2018 to 2022
$2.4MCannabinoid Modulation of Cell FunctionK05DA021696 · NIDA · TRUSTEES OF INDIANA UNIVERSITY · PI MACKIE, KENNETH · 2007 to 2017
$1.3MDesensitization and downregulation of CB1 during cannabinoid toleranceK01DA037355 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MORGAN, DANIEL J · 2015 to 2017
$476kCharacterization of a novel JNK-mediated mechanism of cannabinoid toleranceR21DA036385 · NIDA · PENNSYLVANIA STATE UNIV HERSHEY MED CTR · PI MORGAN, DANIEL J · 2013 to 2014
$400kNIDA NIH HHS K01 DA037355NIDA NIH HHS K05 DA021696NIDA NIH HHS P01 DA009158NIDA NIH HHS R01 DA011322NIDA NIH HHS R01 DA044999NIDA NIH HHS R21 DA036385
Abstract
Tolerance to the antinociceptive effects of cannabinoids represents a significant limitation to their clinical use in managing chronic pain. Tolerance likely results from desensitization and down-regulation of the cannabinoid type 1 receptor (CB
Indexed as
AnalgesicsAnimalsAnthracenesBenzoxazinesCannabinoidsCisplatinDronabinolDrug ToleranceHyperalgesiaJNK Mitogen-Activated Protein KinasesMaleMiceMorpholinesNaphthalenesNeuralgiaPain Measurement(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanoneAnalgesicsAnthracenesBenzoxazinesCannabinoidsCisplatinDronabinolJNK Mitogen-Activated Protein KinasesMorpholinesNaphthalenespyrazolanthroneArrestinCannabinoidCB(1)RGPCRJNKMousePainTHCTolerance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.